Publications by authors named "Neil Formica"

Claim this Profile
S
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination.
Louis Fries, Neil Formica, Raburn M Mallory, Haixia Zhou, Joyce S Plested

J Infect Dis· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Raburn M Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi

Lancet Infect Dis· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
Neil Formica, Raburn Mallory, Gary Albert, Michelle Robinson, Joyce S Plested

PLoS Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
Cheryl Keech, Gary Albert, Iksung Cho, Andreana Robertson, Patricia Reed, Neil Formica

N Engl J Med· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
Jolanta Airey, Frank R Albano, Daphne C Sawlwin, Alison Graves Jones, Neil Formica

Vaccine· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
John T Treanor, Frank R Albano, Daphne C Sawlwin, Alison Graves Jones, Jolanta Airey, Neil Formica

Vaccine· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
Terry Nolan, Peter C Richmond, Neil T Formica, Katja Höschler, Maryanne V Skeljo

Vaccine· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
Terry M Nolan, Peter C Richmond, Maryanne V Skeljo, Georgina Pearce, Gunter Hartel, Neil T Formica

Vaccine· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine.
H Keipp Talbot, Wendy Keitel, Thomas R Cate, John Treanor, James Campbell, Neil Formica

Vaccine· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia.
Anthony T Newall, Julia M L Brotherton, Helen E Quinn, Peter B McIntyre, Josephine Backhouse, Neil Formica

Clin Infect Dis· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis